MediciNova Valuation Multiples

MediciNova Overview

About MediciNova

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.

Founded

2000

HQ

Employees

13

Website

medicinova.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $342K

EBITDA: ($14M)

EV

$43M

Valuation Multiples

Multiples.vc

Start free trial

MediciNova Financials

MediciNova reported last 12-month revenue of $342K and negative EBITDA of ($14M).

In the same LTM period, MediciNova generated $13K in gross profit, ($14M) in EBITDA losses, and had net loss of ($14M).

MediciNova P&L

In the most recent fiscal year, MediciNova reported revenue of $410K and EBITDA of ($13M).

MediciNova expects next 12-month revenue of XXX and NTM EBITDA of XXX

MediciNova Stock Performance

MediciNova has current market cap of $73M, and enterprise value of $43M.

MediciNova's stock price is $1.49.

MediciNova Valuation Multiples

MediciNova trades at 124.8x EV/Revenue multiple, and (3.1x) EV/EBITDA.

MediciNova Financial Valuation Multiples

As of April 11, 2026, MediciNova has market cap of $73M and EV of $43M.

Equity research analysts estimate MediciNova's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

MediciNova has a P/E ratio of (5.3x).

MediciNova Margins & Growth Rates

MediciNova's revenue in the last 12 month declined by (8%).

MediciNova's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.0M for the same period.

MediciNova's rule of 40 is (9059%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

MediciNova's rule of X is (9148%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

MediciNova Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

MediciNova M&A Activity

MediciNova acquired XXX companies to date.

Last acquisition by MediciNova was on XXXXXXXX, XXXXX. MediciNova acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

MediciNova Investment Activity

MediciNova invested in XXX companies to date.

MediciNova made its latest investment on XXXXXXXX, XXXXX. MediciNova invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).